Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation

Annals of Surgery

Volumn 250, Issue 6, 2009, Pages 878-887

  Piessen, Guillaume ^a,b   Messager, Mathieu ^a   Leteurtre, Emmanuelle ^a,b   Jean Pierre, Triboulet ^a,b   Mariette, Christophe ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LINITIS PLASTICA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SIGNET RING CELL; FEMALE; FOLLOW-UP STUDIES; FRANCE; GASTRECTOMY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 73449102148     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b21c7b     Document Type: Article

References (42)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(suppl 2):ii31-ii36.
2. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006;243:64-73.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
4. Watanabe H, Jass JR, Sobin LH. Histological typing of oesophageal and gastric tumors. WHO international histological classification of tumors. 2nd ed. Berlin: Springer-Verlag; 1990.
5. Clark CJ, Thirlby RC, Picozzi V Jr, et al. Current problems in surgery: gastric cancer. Curr Probl Surg. 2006;43:566-670.
6. Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765-770.
7. Novotny AR, Schuhmacher C, Busch R, et al. Predicting individual survival after gastric cancer resection: validation of a US-derived nomogram at a single high-volume center in Europe. Ann Surg. 2006;243:74-81.
8. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adeno-carcinoma resection: eighteen-year experience at a single institution. J Gas-trointest Surg. 2005;9:718-725.
9. Viste A, Eide GE, Halvorsen K, et al. The prognostic value of Lauren's histopathological classification system and ABO blood groups in patients with stomach carcinoma. Eur J Surg Oncol. 1986;12:135-141.
10. Hochwald SN, Kim S, Klimstra DS, et al. Analysis of 154 actual five-year survivors of gastric cancer. J Gastrointest Surg. 2000;4:520-525.
11. Borch K, Jonsson B, Tarpila E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618-626.
12. Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89:1418-1424.
13. Iriyama K, Miki C, Ilunga K, et al. Prognostic significance of histological type in gastric carcinoma with invasion confined to the stomach wall. Br J Surg. 1993;80:890-892.
14. Adachi Y, Kamakura T, Mori M, et al. Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg. 1994;81:414-416.
15. Noda S, Soejima K, Inokuchi K. Clinicopathological analysis of the intestinal type and diffuse type of gastric carcinoma. Jpn J Surg. 1980;10:277-283. (Pubitemid 11132346)
16. Kim JP, Kim SC, Yang HK. Prognostic significance of signet ring cell carcinoma of the stomach. Surg Oncol. 1994;3:221-227.
17. Yokota T, Kunii Y, Teshima S, et al. Signet ring cell carcinoma of the stomach: a clinicopathological comparison with the other histological types. Tohoku J Exp Med. 1998;186:121-130.
18. Li C, Kim S, Lai JF, et al. Advanced gastric carcinoma with signet ring cell histology. Oncology. 2007;72:64-68.
19. Maehara Y, Sakaguchi Y, Moriguchi S, et al. Signet ring cell carcinoma of the stomach. Cancer. 1992;69:1645-1650.
20. Theuer CP, Nastanski F, Brewster WR, et al. Signet ring cell histology is associated with unique clinical features but does not affect gastric cancer survival. Am Surg. 1999;65:915-921.
21. Kunisaki C, Shimada H, Nomura M, et al. Therapeutic strategy for signet ring cell carcinoma of the stomach. Br J Surg. 2004;91:1319-1324.
22. Otsuji E, Yamaguchi T, Sawai K, et al. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol. 1998;67:216-220.
23. Hyung WJ, Noh SH, Lee JH, et al. Early gastric carcinoma with signet ring cell histology. Cancer. 2002;94:78-83.
24. Kim DY, Park YK, Joo JK, et al. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg. 2004;74:1060-1064.
25. Ha TK, An JY, Youn HK, et al. Indication for endoscopic mucosal resection in early signet ring cell gastric cancer. Ann Surg Oncol. 2008;15:508-513
26. Japanese Research Society for Gastric Cancer. The General Rules for the gastric Cancer Study. 1st English ed. Kanahara Shuppan: Tokyo; 1995.
27. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11:127-139
28. Sobin LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002.
29. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
30. Tung SY, Wu CS, Chen PC. Primary signet ring cell carcinoma of colorec-tum: an age-and sex-matched controlled study. Am J Gastroenterol. 1996; 91:2195-2199.
31. Ribeiro MM, Sarmento JA, Sobrinho Simoes MA, et al. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer. 1981;47:780-784.
32. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305-315.
33. Ajani JA, Mansfield PF, Lynch PM, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999;17:2403-2411.
34. Gretschel S, Siegel R, Estevez-Schwarz L, et al. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg. 2006;93: 1530-1535.
35. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
36. Ychou M, Pignon JP, Lasser P, et al. Phase III preliminary results of preoperative fluorouracil and cisplatin versus surgery alone in adenocarci-noma of stomach and lower esophagus: FNLCC 94012-FFCD 9703 trial. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Vol24, No 18S, 2006:4026.
37. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg. 2006;95:270-273.
38. Rougier P, Ducreux M, Mahjoubi M, et al. Efficacy of combined 5-fluorou-racil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer. 1994;30A:1263-1269.
39. Feng J, Al-Abbadi M, Kodali U, et al. Cytologic diagnosis of gastric linitis plastica by endoscopic ultrasound guided fine-needle aspiration. Diagn Cy-topathol. 2006;34:177-179.
40. Mourra N, Fléjou JF. Cancer de l'estomac: anatomie pathologique. Encycl Méd Chir (Editions Scientifiques et Médicales Elsevier SAS, Paris, tous droits réservés). Gastro-entérologie. 2001;9. 9-027-A-05.
41. Walker MJ. A review of carcinoma of the stomach at a tertiary care referral hospital. Am J Surg. 1996;172:75-78.
42. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904-1909.